CliffBio
small molecule

PIPERACILLIN AND TAZOBACTAM

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand namePIPERACILLIN AND TAZOBACTAM
Active ingredientPIPERACILLIN SODIUM; TAZOBACTAM SODIUM
StrengthEQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMay 2018
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.